According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a ...

A bold new program tries to make medicines at the point of care "EQUIP-A-Pharma is about point-of-need manufacturing—hospitals, military bases, disaster zones—ensuring rapid drug availability in ...

Blueprint Medicines Corp (NASDAQ: BPMC) stock has reached an all-time high, hitting a price of 129.49 USD. According to InvestingPro data, the stock’s RSI indicates overbought territory, with ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval for a potential rival to Blueprint Medicines’ Ayvakit.

This is How AI Can Help Us Make New Medicines Faster Federally-funded research has America on the cusp of a new dawn in pharmaceuticals, offering hope for curing the most heartbreaking diseases.

BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.